Central Bank of India (Rs.38.00) (Code: 532885) :- The PSU bank has network of 3513 branches and 237 extension counters accross the country. It is ranked third amongst PSU banks of India. The bank has equity of Rs.404.14 crores. Gross income of the bank was Rs. 5431 crores and net profit was Rs. 155 crores during the quarter ended in September, 2008. EPS during the
period was Rs. 3.85. Book value of the stock is Rs. 80. If we consider the current market price of the scrip of Rs. 38-39 it is available in the market at 0.50 times of the price to book value.Bank is likely to benefit due to further interest rate cut in days to come. Investors may plan investment in the scrip for period of 2 to 3 years to earn 25 to 30 per cent return on investment.
Ahluwalia Contractors (Rs.32.00) (Code: 532811) :- The company, which was established in 1979, is active in the business of engineering procurement. The business includes construction of buildings, malls, multistorage residential complexes, offices, hotels, IT parks and hospitals. Company has earned net profit of Rs. 14.52 crores from net sale of Rs. 301.75 crores during quarter ended in September, 2008. Company has sound order book of Rs. 3750 crores. Company has also bagged biggest housing contract. The township, which is coming up has gross value of Rs. 688 crores. Considering the huge order book and probability of future developement of the company investment in the scrip is likely to prove beneficial for the investors.
Dena Bank (Rs.35.00) (Code: 532121) :- During 3rd quarter ended in December, 2008 financial performance of PSU banks, including Dena Bank has shown good imporvment. Net profit of Dena Bank earned net profit of Rs. 140.36 crores, which shows improvement of 38.87 per cent in comparison to same quarter of previous FY. Gross income of the bank has improved from Rs.804 crores to Rs. 1093 crores during the period,
Unichem Laboratories (151.00) (Code : 506690) :- Have been churning out excellent nos from last few quarters. For the Dec’08 qtr, it recorded whopping 90% increase in net profit to Rs 28 cr with 10% improvement in sales to Rs 152 cr. It posted an impressive OPM of 24% against 17% last fiscal. The Goa and UP plant has already got the US FDA approval whereas MP plant is expected to get it soon. Company has a wide chronic care portfolio with cardiovascular and diabetology therapeutic segments contributing around 50% of the domestic formulations. Lately company has launched new division focusing on Dermatology and has even introduced 15 products of this segment in the market. For FY09 it is estimated to report topline of Rs 650 cr and PAT of Rs110 cr leading an EPS of Rs 31 on current equity of Rs 18 cr having face value as Rs 2/- per share.
Source: Internet (Smart Investment)
